Live Updates > Live Update Details
2025-09-12 16:37:07
Sinopharm Modern Pharmaceuticals' Subsidiary's API Production Line Passes GMP Compliance Inspection: (1) Workshop 108 and related production lines in the integrated API workshop of Sinopharm Weiqida Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Sinopharm Modern Pharmaceuticals, have passed the pharmaceutical GMP compliance inspection. (2) This inspection covered the production qualifications of the API (acarbose) and involved Workshop 108 and Line III of the integrated API workshop. (3) This inspection was the first pharmaceutical GMP compliance inspection for acarbose prior to its launch. (4) The relevant workshops and production lines were all renovation projects of existing factory buildings, with a total construction investment of approximately RMB 22.76 million. (5) The production line currently specializes in the production of acarbose API, with a designed annual production capacity of 12 tons.
